[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"asthma-allergic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:asthma-allergic":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,83,105,126],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100361242","plant-stanol-esters-and-preventing-asthma-symptoms-100361242",false,"NCT03983603","Plant Stanol Esters and Preventing Asthma Symptoms","The Effects of Long-term Daily Plant Stanol Ester Intake on Clinical Symptoms in Individuals With Allergic Asthma: an Exploratory Double-blind Randomized Controlled Trial","PLANTASTIC","Inclusion Criteria:\n\n* Diagnosed with allergic asthma (GINA step 1-4) which is in a stable phase at the moment of inclusion (defined as no changes in asthma control and lung function in (at least) the past three months)\n* Have been treated with prescribed asthma medication for at least one year\n* Aged 18-70 years old\n* BMI between 20 and 35 kg\u002Fm2\n* Willing to abstain from products containing plant sterols or stanols one month prior to the study (products with a cholesterol lowering claim of Becel ProActiv, Benecol, Danacol, store brands)\n* Willing to abstain from products containing plant sterols or stanols during the study (products with a cholesterol lowering claim of Becel ProActiv, Benecol, Danacol, store brands)\n* Willing to keep the intake of fish oil supplements constant\n\nExclusion Criteria:\n\n* Currently smoking or quitted smoking in the past year, with a maximum of 10 packyears as smoking history (packyears = packs per day \\* years of smoking)\n* Allergy to an ingredient of the soft chews\n* Suffering from inflammatory diseases (for CVD, illness must be minimally 3 years ago and currently under control in order to participate in the study)\n* Fasting plasma glucose \\> 7.0 mmol\u002FL\n* Fasting serum TC \\> 8.0 mmol\u002FL\n* Having donated blood within one month prior to the start of the study, or planning to donate blood during the study\n* Pregnant women\n* Breastfeeding women","ALL","18 Years","70 Years",{"count":21,"type":22},160,"ESTIMATED","INTERVENTIONAL",[25],"NA","Plant stanols are known to lower low-density lipoprotein cholesterol. However, studies have suggested that these compounds also influence the immune system. Asthmatic responses are predominantly T helper (Th)2 cell dependent, while plant stanols were previously found to activate Th1 cells and shift the immune response away from the Th2 cell dominant asthmatic response. The question now is whether this also translates into a reduction of clinical symptoms in asthma patients.The primary objective of this study is to demonstrate clinical benefits of prolonged consumption of plant stanols (delivered via plant stanol esters) in asthma patients. The secondary objectives are to evaluate the mechanisms via which plant stanols modulate the immune system and to evaluate the effects of plant stanol ester consumption on cardiovascular (CVD) risk parameters.",[28,29],"Asthma, Allergic","Cardiovascular Diseases",[31,32,33,34],"Plant stanols","Asthma","Immune system","Metabolic health","RECRUITING","2026-06-22",{"date":38,"type":39},"2026-06-25","ACTUAL",{"date":41,"type":39},"2019-04-29",{"date":43,"type":22},"2026-09",{"name":45,"class":46},"Maastricht University Medical Center","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":82},"100431453","phase-3-efficacy-and-safety-evaluation-of-the-treatment-of-allergy-against-cupressaceae-and-grasses-100431453","NCT04898283","Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.","Prospective, Multicentre, Doubleblind, Placebo-controlled RCT to Evaluate Efficacy and Safety With SC Immunotherapy in Patients With Rhinitis\u002FRhinoconjunctivitis With or Without Mild to Moderate Asthma Sensitised to Grasses and Cupressaceae","Inclusion Criteria:\n\n1. Written informed consent.\n2. Aged between 12 and 65, both genders\n3. Positive suggestive clinical history of intermittent or persistent moderate to severe rhinitis \u002Frhinoconjunctivitis according to ARIA classification, with or without moderate intermittent or persistent asthma,according to GEMA 5.0, due to grass and cupressaceae pollen.\n4. Subjects with a positive skin prick-test (wheal size \\>5 mm diameter) to a standardized mixed extract of grass pollen (Phleum pratense, Holcus lanatus, Dactylis glomerata, Poa pratensis, Festuca elatior, Lolium perenne) or to one of the molecular components of the mixture and to a cupressaceae extract. In addition, the largest diameter of the papules must be greater than or equal to that of the histamine.\n5. Specific IgE \\> 3,5 KU\u002FL , against grass (preferably Phleum pratense) and cupressaceae pollen (InmunoCAP® o Immulite).\n6. Women of childbearing age (from menarche) must present a urine pregnancy test with a negative result at the time of joining the trial.\n7. Women of childbearing potential participating in the trial, should commit to using an appropriate method of contraception. Medically acceptable methods of contraception are intrauterine devices placed at least 3 months in advance, surgical sterilization (for example, tubal ligation), barrier methods, or the use of oral contraceptives.\n8. Subjects capable of complying with the dosing regimen.\n9. Subjects who own a smartphone for symptom registration and medication.\n10. Subjects with a negative prick test to coestational pollens. In the case specific IgE is available, the result should be \\\u003C3,5 kU\u002FL and without relevant symptomatology\n11. Subjects with a negative prick test to other aeroallergens (dust mites, epitheliums and fungus). In the case specific IgE is available, the result should be \\\u003C3,5 kU\u002FL and without relevant symptomatology.\n\nExclusion Criteria:\n\n1. Subjects with positive prick test to other aeroallergens except for sensitisation to epithelia with occasional exposure and symptoms.\n2. Subjects with positive prick test to other aeroallergens except for sensitisation to pollen noncoseasonal with cupressus or grasses.\n3. Subjects who have received prior immunotherapy in the preceding 5 years for any of the allergens tested or a cross-reactive allergen or are currently receiving immunotherapy with any allergen.\n4. Subjects in which immunotherapy may be subject to an absolute general contraindication according to the criteria of the Immunotherapy Committee of the Spanish Society of Allergy and Clinical Immunology and the European Allergy and Clinical Immunology Immunotherapy Subcommittee.\n5. Subjects with severe or uncontrolled intermittent or persistent asthma, with an FEV1 \\\u003C70% with respect to the reference value despite adequate pharmacological treatment at the time of inclusion in the trial. Likewise, subjects with intermittent or persistent rhinitis \u002F rhinoconjunctivitis with severe symptoms in which the suspension of oral or systemic antihistamine treatment is contraindicated.\n6. Subjects who have previously had a severe secondary reaction during the prick test diagnostic skin test.\n7. Subjects treated with beta-blockers.\n8. Clinically unstable subjects at the time of inclusion in the trial (acute asthmatic exacerbation, respiratory infection, febrile process, acute urticaria, etc.).\n9. Subjects with active chronic urticaria, severe dermographism, severe atopic dermatitis, sunburn, active psoriasis with lesions in areas where skin tests will be performed, or a history of hereditary angioedema.\n10. Subjects who have any pathology in which adrenaline administration is contraindicated (hyperthyroidism, HTN, heart disease, etc.).\n11. Subjects with any other disease not related to moderate rhinoconjunctivitis or asthma, but potentially serious and that may interfere with treatment and follow-up (epilepsy, psychomotor disorder, uncontrolled diabetes, malformations, multioperated patients, kidney disease,).\n12. Subjects with autoimmune disease (thyroiditis, lupus, etc.), tumor diseases or with a diagnosis of immunodeficiencies.\n13. Subject whose condition prevents from offering cooperation and\u002F or who has severe psychiatric disorders.\n14. Subjects with a known allergy to components of the investigational medicinal product other than the allergen.\n15. Subjects with lower respiratory diseases other than asthma such as emphysema or bronchiectasis.\n16. Subjects who are direct relatives of the researchers.\n17. Pregnant or lactating women.","12 Years","65 Years",{"count":58,"type":22},180,[60],"PHASE3","A Randomized, Double-Blinded, Placebo-Controlled, Prospective, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Immunotherapy in Patients With Rhinitis\u002FRhinoconjunctivitis With or Without Mild to Moderate Asthma Sensitized to cupressaceae and grasses.",[63,64,28],"Rhinitis, Allergic","Rhinoconjunctivitis",[66,67,68,69,70,71],"Rhinitis\u002F Rhinoconjunctivitis","Mild to moderate asthma","Allergy","Immunotherapy","Grass","cupressaceae","2025-05-07",{"date":74,"type":39},"2025-05-13",{"date":76,"type":39},"2021-05-31",{"date":78,"type":22},"2026-10",{"name":80,"class":81},"Inmunotek S.L.","INDUSTRY",27,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":94,"conditions":95,"keywords":96,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":98,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},"100395968","phase-3-efficacy-and-safety-evaluation-for-the-treatment-of-allergy-against-mites-100395968","NCT04435990","Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites","Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Clinical Trial With SCIT in Patients With Rhinitis\u002FRhinoconjunctivitis With or Without Mild to Moderate Asthma Sensitized to Dpt. and\u002For D. Farinae","MM09-SIT-023","Inclusion Criteria:\n\n* Written informed consent.\n* Age between 12 and 65, both genders.\n* Subjects with a confirmed clinical history of inhalant allergy (intermittent or persistent moderate-severe rhinitis and\u002For rhinoconjunctivitis according to the ARIA classification with or without intermittent or persistent mild-moderate controlled asthma according to the GEMA 5.0 definition) caused by allergy to Dermatophagoides pteronyssinus and\u002For Dermatophagoides farinae. The diagnosis of asthma will be valid from 12 months prior to signing the informed consent.\n* Subjects with a positive skin prick-test wheal size \\>5 mm higher diameter due to Dermatophagoides pteronyssinus and\u002For Dermatophagoides farinae. The positive and negative control of the test should give consistent results. The results will be valid 12 months prior to the signing of the informed consent.\n* Specific immunoglobulin E against house dust mites \\>3,5 KU\u002FmL (InmunoCAP® o Immulite), for the complete extract of Dermatophagoides pteronyssinus and \u002F or for Dermatophagoides farinae or for some of the molecular components of these allergenic sources\n* Subjects should preferably be monosensitized to the study allergens. In case of subjects sensitized to other aeroallergens, only those with the following characteristics may be included in the study:\n\n  * Subjects with positive skin test to Blomia tropicalis and Lepidoglyphus destructor, whose specific IgE values do not exceed or equal the values for the study allergens. The maximum specific IgE value for these allergens is 3.5 KU\u002FL.\n  * Subjects with positive skin tests to epithelia, as long as they present occasional exposure and symptomatology.\n  * Subjects with positive skin tests to pollens, whose specific IgE values do not exceed or equal the values of the allergens in the study and who do not present exacerbations during the pollen season. The maximum value of specific IgE for these allergens is 17.5 KU\u002FL.\n* Subjects with negative skin test for fungi\n* Women of childbearing age (from menarche) must present a urine pregnancy test with a negative result at the time of joining the trial, before the first administration of the IMP.\n* Women of childbearing age participating in the trial must agree to use an appropriate method of contraception, meaning any act, device, or medication to prevent conception or viable pregnancy, during the trial if they are sexually active.\n* Subjects with a diagnosis of asthma according to the GEMA 5.0 guideline.\n* Subjects capable of complying with the dosing regimen.\n* Subjects who own an smartphone for symptom registration and medication\n\nExclusion Criteria:\n\n* Subjects who have received previous immunotherapy in the previous 5 years to dander, fungi, and mites.\n* Subjects in whom immunotherapy may be subject to an absolute general contraindication according to the criteria of the Immunotherapy Committee of the Spanish Society of Allergy and Clinical Immunology and the European Allergy and Clinical Immunology Immunotherapy Subcommittee.\n* Subjects with persistent severe or uncontrolled asthma, with an FEV1\\\u003C70% of baseline despite adequate pharmacological treatment at the time of inclusion in the trial. Also subjects with intermittent or persistent rhinitis\u002Frhinoconjunctivitis with severe symptoms in whom oral or systemic antihistamine therapy is contraindicated.\n* Subjects who have previously presented a serious secondary reaction during the performance of diagnostic skin tests using the prick test.\n* Subjects under treatment with β-blockers.\n* Clinically unstable subjects at the time of inclusion in the trial (acute asthma exacerbation, respiratory infection, feverish process, acute urticaria, etc.).\n* Subjects with chronic active urticaria, severe dermographism, severe atopic dermatitis, sunburn, active psoriasis with lesions in areas where skin prick test will be performed, or a history of hereditary angioedema.\n* Subjects with any other disease not related to moderate rhinoconjunctivitis or asthma, but of potential severity and that may interfere with treatment and follow-up (epilepsy, psychomotor impairment, uncontrolled diabetes, malformations, multiple surgeries, nephropathy).\n* Subjects with autoimmune disease (thyroiditis, lupus, etc.), tumor diseases or with a diagnosis of immunodeficiencies.\n* Subject whose condition prevents him\u002Fher from offering cooperation and\u002For who has serious mental illness.\n* Subjects with a known allergy to other components of the investigational medicinal product other than the allergen.\n* Subjects with diseases of the lower respiratory tract other than asthma such as emphysema or bronchiectasis.\n* Direct investigator's relatives.\n* Pregnant women or breastfeeding women.",{"count":92,"type":22},150,[60],"A double-blinded, placebo-controlled, prospective, multicenter randomized of 2 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with rhinitis\u002Frhinoconjunctivitis with or without asthma, sensitised to Dermatophagoides pteronyssinus and \u002For Dermatophagoides farinae.",[63,64,28],[66,67,68,69,97],"Mites",{"date":74,"type":39},{"date":100,"type":39},"2020-10-06",{"date":102,"type":22},"2026-12",{"name":80,"class":81},32,{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":113,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":104},"100430911","phase-3-efficacy-and-safety-evaluation-for-the-treatment-of-allergy-against-grass-and-olive-pollen-100430911","NCT04891237","Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen","A Randomized, Double-Blinded, Placebo-Controlled, Prospective, Multicenter CT to Evaluate Efficacy and Safety of Subcutaneous Immunotherapy in Subjects With Rhinitis With\u002FWithout Mild to Moderate Asthma Sensitized to Olive and Grass Pollen","Inclusion Criteria:\n\n1. Subject who has signed the informed consent.\n2. Subjects of both sexes aged between 12 and 65 years.\n3. Subjects with confirmed clinical history of inhalational allergy (rhinitis and \u002F or moderate-severe intermittent or persistent rhinoconjunctivitis according to the ARIA classification with or without intermittent or persistent controlled mild-moderate asthma according to the GEMA 5.0 classification caused by grass and olive allergy. The diagnosis of asthma will be valid from 12 months prior to signing the informed consent\n4. Subjects with a positive prick test (higher papule diameter ≥ 5 mm) to a standardized extract of pollen from grasses (Phleum pratense, Holcus lanatus, Dactylis glomerata, Poa pratensis, Festuca elatior, Lolium perenne), or one of the components of the mixture and an olive extract.\n5. Specific IgE (CAP or Immulite) against a mixture of grasses or against one of the components of the mixture of grasses, preferably Phleum pratense and olive or one of the molecular components of allergenic sources with a value \\> 3,5 KU \u002F L.\n6. Women of childbearing age (from menarche) should submit a urine pregnancy test with a negative result at the time of joining the trial.\n7. Women of childbearing potential, and men participating in the trial, should commit to using an appropriate method of contraception. Medically acceptable methods of contraception are intrauterine devices placed at least 3 months in advance, surgical sterilization (for example, tubal ligation), barrier methods, or the use of oral contraceptives.\n8. Subjects capable of complying with the dosage regimen.\n9. Subjects who have a smartphone to record symptoms and medication.\n10. Subjects with a negative prick test to coestational pollens. In the case specific IgE is available, the result should be \\\u003C3,5 kU\u002FL and without relevant symptomatology\n11. Subjects with a negative prick test to other aeroallergens (dust mites, epitheliums and fungus). In the case specific IgE is available, the result should be \\\u003C3,5 kU\u002FL and without relevant symptomatology\n\nExclusion Criteria:\n\n1. Subjects polysensitized to other aeroallergens with the exception of epithelia with occasional exposure and symptoms\n2. Subjects polysensitized to other aeroallergens with the exception non-seasonal pollens with grasses and olive\n3. Subjects who have received prior immunotherapy in the preceding 5 years to any aeroallergens.\n4. Subjects in which immunotherapy may be subject to an absolute general contraindication according to the criteria of the Immunotherapy Committee of the Spanish Society of Allergy and Clinical Immunology and the European Allergy and Clinical Immunology Immunotherapy Subcommittee.\n5. Subjects with severe or uncontrolled persistent asthma, with an FEV1 \\\u003C70% with respect to the reference value despite adequate pharmacological treatment at the time of inclusion in the trial. Likewise, subjects with intermittent or persistent rhinitis \u002F rhinoconjunctivitis with severe symptoms in which the suspension of oral or systemic antihistamine treatment is contraindicated.\n6. Subjects who have previously presented a serious secondary reaction during the performance of diagnostic skin tests using the prick test.\n7. Subjects under treatment with ß-blockers.\n8. Clinically unstable subjects at the time of enrolment in the trial (acute asthma exacerbation, respiratory infection, feverish process, acute urticaria, etc.).\n9. Subjects with active chronic urticaria, severe dermographism, severe atopic dermatitis, sunburns, active psoriasis with lesions in areas where skin tests will be performed, or a history of hereditary angioedema.\n10. Subjects who have any pathology in which the administration of adrenaline is contraindicated (hyperthyroidism, HT, heart disease, etc.).\n11. Subjects with some other disease not related to moderate rhinoconjunctivitis or asthma, but of potential severity and that may interfere with treatment and follow-up (epilepsy, psychomotor disorder, uncontrolled diabetes, malformations, multiple operations, kidney disease,).\n12. Subjects with autoimmune disease (thyroiditis, lupus, etc.), tumor diseases or with a diagnosis of immunodeficiencies.\n13. Subject whose condition prevents him \u002F her from offering cooperation and who has severe psychiatric disorders.\n14. Subjects with a known allergy to other investigational drug components other than the allergen.\n15. Subjects with diseases of the lower respiratory tract other than asthma such as emphysema or bronchiectasis.\n16. Subjects who are direct relatives of the researchers.\n17. Pregnant or lactating women.",{"count":58,"type":22},[60],"Prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial of efficacy and safety with subcutaneous immunotherapy in patients with mild to moderate rhinitis \u002F rhinoconjunctivitis with or without mild to moderate asthma sensitized to grasses and olive",[63,64,28],[66,67,68,117,118],"Grasses","Olea","2025-05-05",{"date":72,"type":39},{"date":122,"type":39},"2021-06-14",{"date":124,"type":22},"2027-01",{"name":80,"class":81},{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":134,"targetDuration":4,"studyType":23,"phases":135,"briefSummary":137,"conditions":138,"keywords":139,"overallStatus":144,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":4},"100518171","phase-4-biologics-and-sublingual-immunotherapy-100518171","NCT06027073","Biologics and Sublingual Immunotherapy","Adding Biological Therapy to Asthmatic Patients on Allergen Immunotherapy to House Dust Mites","BSIPL","Inclusion Criteria:• \\>18 years old\n\n* A total IgE between 30-700 IU\u002FmL\n* Moderate asthma with perennial symptoms confirmed as HDM-driven asthma based on medical history and positive nasal provocation tests, partially controlled asthma;\n* FEV1 \\>70% at baseline;\n* Positive skin prick test results for D. pteronyssinus, D. farinae\n\nExclusion Criteria:\n\n* Sensitisation to other allergens with clinical signs not related to HDM\n* Uncontrolled asthma,\n* Other serious diseases or chronic unstable diseases\n* Allergen immunotherapy during the past 5 years\n* Contraindicating allergen immunotherapy and omalizumab treatment.",{"count":92,"type":22},[136],"PHASE4","Most current studies involve using a biological drug to increase the safety of allergen immunotherapy (AIT) especially in the treatment of food allergies, to avoid the risk of anaphylaxis. However, adding Xolair® to AIT may improve the therapy's effectiveness. There are still few observations on this topic, especially in patients with house dust mite (HDM)-driven asthma.",[28],[140,141,142,143],"IgE","asthma","omalizumab","immunotherapy","NOT_YET_RECRUITING","2023-08-30",{"date":147,"type":39},"2023-09-07",{"date":149,"type":22},"2024-05-01",{"date":151,"type":22},"2028-03-01",{"name":153,"class":46},"Medical University of Silesia"]